Don joined Advent in 2007 after 25 years as a biotech entrepreneur and chief executive. He co-founded Medarex, Genmab, and Celldex Therapeutics, all of which grew to be multi-billion dollar companies.
Don has overseen the progression of numerous innovative therapeutics from research concept to clinical trials, including the pioneering cancer treatments Yervoy® and Opdivo®, which were recognized in the 2018 Nobel Prize.
Don is a Fellow in Health Management and co-lead of the Biopharmaceutical Initiative at the University of Cambridge Judge School of Business. He is also a co-author of the book From Breakthrough to Blockbuster: The Business of Biotechnology, a Financial Times Top Business Title. He received an AB from Dartmouth College, a JD from Columbia University and a PhD from Princeton University.
Don takes Advisory, Board and senior non-executive roles with our portfolio companies, including 4-antibody, Capella Biosciences, Aleta, and Manta Medicines.
We use our own and third party cookies that are essential to make our website work. We also use other cookies for analytics on site usage to help us improve our site and give you an easy and personalised experience. You can 'Accept All' other cookies or customise your preferences to reject or permit specific cookies by visiting "Cookie Consent" and selecting "Cookie Settings" in the pop-up at the bottom of the window.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.